Deutsche Bank AG Increases Halozyme Therapeutics, Inc. (HALO) Price Target to $20.00

Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price target increased by Deutsche Bank AG to $20.00 in a research report sent to investors on Friday. Deutsche Bank AG currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on HALO. Piper Jaffray Companies set a $20.00 target price on Halozyme Therapeutics and gave the stock a buy rating in a research note on Thursday, August 10th. BidaskClub downgraded Halozyme Therapeutics from a hold rating to a sell rating in a research report on Friday, August 18th. Jefferies Group LLC reiterated an underperform rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Zacks Investment Research upgraded Halozyme Therapeutics from a hold rating to a buy rating and set a $14.00 price target on the stock in a research report on Friday, August 11th. Finally, Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the stock a buy rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $16.00.

Shares of Halozyme Therapeutics (NASDAQ HALO) opened at 16.72 on Friday. Halozyme Therapeutics has a 52 week low of $8.18 and a 52 week high of $17.55. The company’s market cap is $2.24 billion. The company’s 50-day moving average price is $12.90 and its 200 day moving average price is $13.26.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter in the previous year, the company earned ($0.21) EPS. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Equities research analysts anticipate that Halozyme Therapeutics will post ($0.88) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Deutsche Bank AG Increases Halozyme Therapeutics, Inc. (HALO) Price Target to $20.00” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/19/deutsche-bank-ag-increases-halozyme-therapeutics-inc-halo-price-target-to-20-00.html.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its position in Halozyme Therapeutics by 4.8% during the second quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after purchasing an additional 532,658 shares in the last quarter. Iridian Asset Management LLC CT boosted its position in Halozyme Therapeutics by 2.0% during the second quarter. Iridian Asset Management LLC CT now owns 10,608,993 shares of the biopharmaceutical company’s stock worth $136,007,000 after purchasing an additional 208,605 shares in the last quarter. Vanguard Group Inc. boosted its position in Halozyme Therapeutics by 9.5% during the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after purchasing an additional 831,654 shares in the last quarter. BB Biotech AG boosted its position in Halozyme Therapeutics by 6.7% during the second quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock worth $105,961,000 after purchasing an additional 515,472 shares in the last quarter. Finally, Senzar Asset Management LLC boosted its position in Halozyme Therapeutics by 17.1% during the second quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock worth $52,399,000 after purchasing an additional 597,400 shares in the last quarter. Institutional investors own 85.06% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply